Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

58.66USD
29 Jul 2016
Change (% chg)

$0.23 (+0.39%)
Prev Close
$58.43
Open
$59.01
Day's High
$59.20
Day's Low
$58.27
Volume
8,491,237
Avg. Vol
8,658,637
52-wk High
$60.07
52-wk Low
$45.69

MRK

Chart for MRK

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment... (more)

Overall

Beta: 0.66
Market Cap(Mil.): $162,372.41
Shares Outstanding(Mil.): 2,768.02
Dividend: 0.46
Yield (%): 3.14

Financials

  MRK Industry Sector
P/E (TTM): 32.13 39.19 39.69
EPS (TTM): 1.83 -- --
ROI: -- 15.23 14.44
ROE: -- 16.16 15.49

Merck quarterly results beat forecasts, shares rise

Merck & Co reported better-than-expected quarterly earnings, fueled by sales of its new Keytruda immuno-oncology drug and Januvia diabetes treatment, sending its shares up 2 percent in premarket trading.

Jul 29 2016

UPDATE 2-Merck quarterly results beat forecasts, shares rise

July 29 Merck & Co reported better-than-expected quarterly earnings, fueled by sales of its new Keytruda immuno-oncology drug and Januvia diabetes treatment, sending its shares up 2 percent in premarket trading.

Jul 29 2016

Merck & Co reports 1 pct rise in quarterly revenue

July 29 Merck & Co Inc reported a 1 percent rise in quarterly revenue, driven by higher sales of its cancer drug, Keytruda.

Jul 29 2016

BRIEF-Merck Q2 adjusted earnings per share $0.93

* Q2 januvia/janumet sales $ 1,634 million versus $1,412 million in q1

Jul 29 2016

U.S. probes contracts between Eli Lilly and PBMs

By Ankur Banerjee Eli Lilly and Co said it received a civil investigative demand from the U.S. attorney's office for the southern district of New York, requesting documents and information relating to contracts with pharmacy benefit managers (PBMs).

Jul 28 2016

U.S. probes contracts between Eli Lilly and PBMs

Eli Lilly and Co said it received a civil investigative demand from the U.S. attorney's office for the southern district of New York, requesting documents and information relating to contracts with pharmacy benefit managers (PBMs).

Jul 28 2016

UPDATE 1-U.S. probes contracts between Eli Lilly and PBMs

July 28 Eli Lilly and Co said it received a civil investigative demand from the U.S. attorney's office for the southern district of New York, requesting documents and information relating to contracts with pharmacy benefit managers (PBMs).

Jul 28 2016

Gilead, Merck lock horns on legal fees in hepatitis C patent fight

Gilead Sciences Inc urged a California federal judge on Tuesday to not put off a decision on whether it is owed $15.5 million in legal fees in a patent fight over a lucrative cure for hepatitis C with drugmaker Merck & Co.

Jul 28 2016

Merck seeks to curb plaintiff firm's 'misleading' communications

Merck & Co Inc has asked a New Jersey federal judge to order law firm Sanford Heisler, which is representing plaintiffs in a sex discrimination lawsuit against the company, to stop what it called misleading communications to potential class members.

Jul 28 2016

BRIEF-Merck plans to end partnership agreement with Alk Abello

* Said on Tuesday MSD (known as Merck in the United States and Canada) had informed ALK of its plans to end their partnership agreement

Jul 27 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Wright Reports
$75.00
Provider : New Constructs, LLC
$25.00
Provider : Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.